175 related articles for article (PubMed ID: 38538867)
1. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
Rappaport AR; Kyi C; Lane M; Hart MG; Johnson ML; Henick BS; Liao CY; Mahipal A; Shergill A; Spira AI; Goldman JW; Scallan CD; Schenk D; Palmer CD; Davis MJ; Kounlavouth S; Kemp L; Yang A; Li YJ; Likes M; Shen A; Boucher GR; Egorova M; Veres RL; Espinosa JA; Jaroslavsky JR; Kraemer Tardif LD; Acrebuche L; Puccia C; Sousa L; Zhou R; Bae K; Hecht JR; Carbone DP; Johnson B; Allen A; Ferguson AR; Jooss K
Nat Med; 2024 Apr; 30(4):1013-1022. PubMed ID: 38538867
[TBL] [Abstract][Full Text] [Related]
2. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
Palmer CD; Rappaport AR; Davis MJ; Hart MG; Scallan CD; Hong SJ; Gitlin L; Kraemer LD; Kounlavouth S; Yang A; Smith L; Schenk D; Skoberne M; Taquechel K; Marrali M; Jaroslavsky JR; Nganje CN; Maloney E; Zhou R; Navarro-Gomez D; Greene AC; Grotenbreg G; Greer R; Blair W; Cao MD; Chan S; Bae K; Spira AI; Roychowdhury S; Carbone DP; Henick BS; Drake CG; Solomon BJ; Ahn DH; Mahipal A; Maron SB; Johnson B; Rousseau R; Yelensky R; Liao CY; Catenacci DVT; Allen A; Ferguson AR; Jooss K
Nat Med; 2022 Aug; 28(8):1619-1629. PubMed ID: 35970920
[TBL] [Abstract][Full Text] [Related]
3. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
4. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
5. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
7. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
Sci China Life Sci; 2021 Dec; 64(12):2144-2152. PubMed ID: 33740187
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.
Li F; Deng L; Jackson KR; Talukder AH; Katailiha AS; Bradley SD; Zou Q; Chen C; Huo C; Chiu Y; Stair M; Feng W; Bagaev A; Kotlov N; Svekolkin V; Ataullakhanov R; Miheecheva N; Frenkel F; Wang Y; Zhang M; Hawke D; Han L; Zhou S; Zhang Y; Wang Z; Decker WK; Sonnemann HM; Roszik J; Forget MA; Davies MA; Bernatchez C; Yee C; Bassett R; Hwu P; Du X; Lizee G
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244308
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
[TBL] [Abstract][Full Text] [Related]
10. Computational Prediction and Validation of Tumor-Associated Neoantigens.
Roudko V; Greenbaum B; Bhardwaj N
Front Immunol; 2020; 11():27. PubMed ID: 32117226
[TBL] [Abstract][Full Text] [Related]
11. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
12. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Yarchoan M; Gane EJ; Marron TU; Perales-Linares R; Yan J; Cooch N; Shu DH; Fertig EJ; Kagohara LT; Bartha G; Northcott J; Lyle J; Rochestie S; Peters J; Connor JT; Jaffee EM; Csiki I; Weiner DB; Perales-Puchalt A; Sardesai NY
Nat Med; 2024 Apr; 30(4):1044-1053. PubMed ID: 38584166
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen landscape in metastatic nasopharyngeal carcinoma.
Lin M; Zhang XL; You R; Yang Q; Zou X; Yu K; Liu YP; Zou RH; Hua YJ; Huang PY; Wang J; Zhao Q; Jiang XB; Tang J; Gu YK; Yu T; He GP; Xie YL; Wang ZQ; Liu T; Chen SY; Zuo ZX; Chen MY
Theranostics; 2021; 11(13):6427-6444. PubMed ID: 33995666
[No Abstract] [Full Text] [Related]
14. A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors.
Fang Y; Mo F; Shou J; Wang H; Luo K; Zhang S; Han N; Li H; Ye S; Zhou Z; Chen R; Chen L; Liu L; Wang H; Pan H; Chen S
Clin Cancer Res; 2020 Sep; 26(17):4511-4520. PubMed ID: 32439700
[TBL] [Abstract][Full Text] [Related]
15. The role of neoantigens in tumor immunotherapy.
Shang S; Zhao Y; Qian K; Qin Y; Zhang X; Li T; Shan L; Wei M; Xi J; Tang B
Biomed Pharmacother; 2022 Jul; 151():113118. PubMed ID: 35623169
[TBL] [Abstract][Full Text] [Related]
16. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
17. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical development of neoantigen vaccines.
Li L; Goedegebuure SP; Gillanders WE
Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
[TBL] [Abstract][Full Text] [Related]
19. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Su S; Chen F; Xu M; Liu B; Wang L
Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
